How does cagrilintide behave on a C8 column compared to tirzepatide?

Details up front: cagrilintide · a C8 column · tirzepatide.

I have used one of these for a while and I am considering switching, which requires a reason.

What I care about is reproducibility, because a result I cannot repeat is not useful to me.

So which one, and on what grounds?

It helps to be literal here: peak shape carries as much information as peak area does, and a badly tailing peak or a shouldered peak is telling you something about the sample or the column that matters.

System suitability checks on replicate injections of a known standard establish whether the method was in control — if the peak area varies by more than two per cent between replicates, something is wrong.

The part that matters: mobile phase pH at the point where you inject must match the mobile phase pH at the start of the gradient, or the sample will not be focused at the column head.

The caveat is that HPLC is a purity technique and says almost nothing about whether the main peak is actually your target compound — that is why identity confirmation from mass spectrometry or peptide mapping matters.

The practical summary: specify the method, run the same method on every sample you compare, and use orthogonal techniques to confirm the result.

edited 9 Jul 2024 by RP_C18 — removed a claim I could not source

On the detail: reverse-phase HPLC is the workhorse for peptide purity work, but it is almost universally run under conditions that are not optimal for a peptide of this chain length.

The 214 nanometre wavelength is chosen because it corresponds to the amide backbone absorption, making response roughly proportional to the number of peptide bonds.

Concretely, formic acid is the compromise when you need the mass spectrometer on the same run, but the peak shape penalty is real and easily a tenth of a per cent on purity.

The limitation is that co-elution is invisible — if two species happen to have the same retention time, they will report as a single peak at their combined area.

If two labs give different numbers, the method difference is the first hypothesis, not lab quality.

edited 10 Jun 2024 by petra_hovland — expanded the table to cover the lower concentration

The underlying point is that high-performance liquid chromatography is a separation technique, not an identification technique, and it answers the question "how much of the detected signal is a single species" not "which species is it."

Proline-rich sequences are particularly problematic because the isomerisation kinetics are in the same timescale as the separation, leading to split or broadened peaks at low temperature.

In practice, trifluoroacetic acid at 0.1 per cent is the standard ion-pairing agent because it suppresses tailing by neutralising the basic residues, but it also suppresses mass spectrometry signal.

Worth noting that the achievable resolution depends on the chemistry of the molecule — some peptide sequences separate easily while others are notoriously difficult regardless of method.

Ask for the chromatogram and the system suitability data, not just the number.

To be exact about it, start by understanding what the detector is measuring and what that means about how the molecule needs to be prepared and handled before injection.

Acetonitrile is the organic modifier of choice because it has a good UV cutoff, a reasonable viscosity and a refractive index that minimises baseline noise.

One qualification: the limit of detection on a reversed-phase HPLC is set by the noise on the baseline, which for these molecules is usually in the range of a tenth of one per cent or less, and anything smaller is not reproducibly detectable.

The practical summary: specify the method, run the same method on every sample you compare, and use orthogonal techniques to confirm the result.

The method is the measurement in reverse-phase chromatography, more so than in almost any other analytical domain, and two methods that look identical can easily produce different results.

Sample preparation is almost always under-appreciated — a reconstituted peptide in strong solvent will distort its own peak on the gradient.

Peptide separation by reverse-phase high-performance liquid chromatography is described in the general chapters of the United States Pharmacopeia, European Pharmacopeia and Japanese Pharmacopeia, and the methods converge on essentially the same principles.

If two labs give different numbers, the method difference is the first hypothesis, not lab quality.